Status:
COMPLETED
Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects
Lead Sponsor:
GlaxoSmithKline
Conditions:
Sedation
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The study will evaluate the pharmaco-economic consequences of the use of a remifentanil based regimen compared with a conventional sedative based regimen in terms of duration of mechanical ventilation...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- ICU patients with an expected duration of mechanical ventilation for 2 to 3 days and requiring analgesia and sedation.
- Exclusion criteria:
- ICU patients resuscitated in the previous 24 hours, neurotrauma or expecting major surgery, not likely to survive of with limit care status.
Exclusion
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
224 Patients enrolled
Trial Details
Trial ID
NCT00158873
Start Date
September 1 2004
Last Update
October 16 2008
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
's-Hertogenbosch, Netherlands, 5211 RW
2
GSK Investigational Site
Alkmaar, Netherlands, 1815 JD
3
GSK Investigational Site
Amsterdam, Netherlands, 1081 HV
4
GSK Investigational Site
Apeldoorn, Netherlands, 7334 DZ